roger sabbadini phd professor of biology san diego state university san diego ca n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Roger Sabbadini, PhD Professor of Biology San Diego State University San Diego, CA PowerPoint Presentation
Download Presentation
Roger Sabbadini, PhD Professor of Biology San Diego State University San Diego, CA

Loading in 2 Seconds...

play fullscreen
1 / 11

Roger Sabbadini, PhD Professor of Biology San Diego State University San Diego, CA - PowerPoint PPT Presentation


  • 171 Views
  • Uploaded on

Sphingolipids for ischemia detection. Roger Sabbadini, PhD Professor of Biology San Diego State University San Diego, CA. Sphingolipids. What are they?. Naturally occurring signaling molecules in cells. Released by heart cells lacking sufficient oxygen supply. . Sphingolipids.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

Roger Sabbadini, PhD Professor of Biology San Diego State University San Diego, CA


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
roger sabbadini phd professor of biology san diego state university san diego ca

Sphingolipids for ischemia detection

Roger Sabbadini, PhD

Professor of Biology

San Diego State University

San Diego, CA

sphingolipids
Sphingolipids

What are they?

  • Naturally occurring signaling molecules in cells.
  • Released by heart cells lacking sufficient oxygen supply.
sphingolipids1
Sphingolipids

MIRF trial

Myocardial Ischemia Rating Function trial

318 consecutive patients undergoing cardiac catheterization for all causes.

Sphingosine-1-phosphate (S1P) levels correlated to angiographically demonstrable stenosis. (p<.001)

sphingolipids2
Sphingolipids

MIRF trial: effectiveness

Accuracy maintained across age, gender, and clinical presentation.

Particularly effective in the “active ischemia group” (Patients hospitalized for their symptoms and eventually displayed multi-vessel disease)

Both the incidence and severity of disease tracked to sphingolipids.

sphingolipids3
Sphingolipids

Comparisons to other tests

Other tests measure risk factors, not the presence of active disease.

Sphingolipids detect the presence of ischemic tissue.

sphingolipids4
Sphingolipids

Potential uses

General yearly screening

Triage in emergency department

Evaluation of therapeutic efficacy

sphingolipids5
Sphingolipids

Potential uses: triage

Able to distinguish cardiac-related chest pain from other causes

Sphingolipids may appear earlier than other markers of ischemia (troponin, CKMB)

sphingolipids6
Sphingolipids

Potential uses: efficacy evaluation

Evaluate procedures and medications that reduce ischemia associated with coronary artery disease.

MIRF-2 will measure sphingolipids before and after balloon angioplasty.

sphingolipids7
Sphingolipids

Other ischemia

It may be possible to detect microvascular ischemia in the heart as well as forms of ischemia not related to obstructive disease (heart failure, cardiomyopathy).

sphingolipids8
Sphingolipids

FDA approval

Plan to submit for FDA approval in late 2001.

Two other trials underway.

Don’t expect FDA approval before 2002.